Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Inventiva Pharma logo — A clinical-stage biopharmaceutical company focused on the de...

Inventiva Pharma

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.

Founded 2012 France France 108 employees Post Ipo Equity Total: $276.30M Biopharma, Biotechnology +1

General Information

Company Name Inventiva Pharma
Founded Year 2012
Location France France +2
Employees 108
Industries Biopharma, Biotechnology, Medical Devices
Funding Stage Post Ipo Equity
Social

Get notified when Inventiva Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Inventiva Pharma

Inventiva Pharma, founded in 2012 and headquartered in France, is a clinical-stage biopharmaceutical company specializing in developing oral small molecule therapies for critical unmet medical needs. Their research targets areas such as fibrosis, lysosomal storage disorders, and oncology, with specific programs focusing on NASH, MPS, and oncology indications.

The company operates within the Biopharma, Biotechnology, and Medical Devices industries, aiming to address significant gaps in current therapeutic offerings. Recent financial backing includes a substantial €115.60M Post-IPO Equity investment from a robust consortium of investors—specifically New Enterprise Associates, Sofinnova Partners, Invus, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Schonfeld Strategic Advisors, Great Point Partners, Eventide, and Biotechnology Value Fund—as of October 14, 2024.

Taxonomy: Biopharmaceutical, Clinical-stage, Oral Small Molecule Therapies, Fibrosis, Lysosomal Storage Disorders, Oncology, NASH (Nonalcoholic Steatohepatitis), MPS (Mucopolysaccharidoses), SSc (Systemic Sclerosis), Drug Discovery, Nuclear Receptors, Transcription Factors, Epigenetic Modulation, Proprietary Molecules, Research and Development

Services & Products

Development of oral small molecule therapies
Clinical trials and research programs
Drug candidate development for unmet medical needs

Target Customers

Patients with fibrosis Patients with lysosomal storage disorders Patients with oncology needs Health care providers and researchers focusing on NASH and MPS

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity €115.60M 10
New Enterprise Associates Sofinnova Partners Invus Deep Track Capital Perceptive Advisors Samsara BioCapital Schonfeld Strategic Advisors Great Point Partners
Eventide, Biotechnology Value Fund 		14 Oct 2024
Post-IPO Debt €25.00M 1 European Investment Bank 10 Jan 2024
Post-IPO Equity €35.70M 3
Sofinnova Partners
Yiheng Capital, Qatar Holding 		31 Aug 2023
Post-IPO Debt €25.00M 1 European Investment Bank 16 May 2022
Post-IPO Debt €10.00M - 19 May 2020

View All 10 Funding Rounds

Inventiva Pharma Alternatives & Competitors

Inventiva Pharma vs
3B Pharmaceuticals GmbH
3B Pharmaceuticals GmbH Germany

3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, German...

44 employees
Biotechnology
Inventiva Pharma vs
Exiris s.r.l.
Exiris s.r.l. Italy

Preclinical stage company focused on oncology research

6 employees
Inventiva Pharma vs
Theratechnologies Inc.
Theratechnologies Inc. Canada

Health innovation that matters | #HIV #NASH #Oncology

Post Ipo Equity
98 employees
Biotechnology, Pharmaceutical
Compare Inventiva Pharma vs Theratechnologies Inc.
Also compare with: Inventiva Pharma vs Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited Inventiva Pharma vs TCD Pharma TCD Pharma

FAQ About Inventiva Pharma

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies.
Inventiva Pharma was founded in 2012.
Inventiva Pharma is headquartered in France.
Inventiva Pharma operates in the following industries: Biopharma, Biotechnology, Medical Devices.
Inventiva Pharma has approximately 108 employees.
Inventiva Pharma has completed 10 funding rounds, raising a total of $276.30M. The latest funding stage is Post Ipo Equity.
Inventiva Pharma offers: Development of oral small molecule therapies, Clinical trials and research programs, Drug candidate development for unmet medical needs.
Top alternatives and competitors to Inventiva Pharma include 3B Pharmaceuticals GmbH, Exiris s.r.l., Theratechnologies Inc., Telix Pharmaceuticals Limited, TCD Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inventiva Pharma and 3B Pharmaceuticals GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Inventiva Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy